We recently identified ceramide as a ligand for CD300f and demonstrated that the binding of extracellular ceramide to CD300f inhibits IgE- or ATP-mediated mast cell activation via its ITIMs and ITSM, in allergic responses or colitis, respectively, in mouse models (9, 10). Here, CD300LF is linked to colitis.